Gain Therapeutics Inc Dossier - Source-backed chat

Gain Therapeutics Inc

GANXNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.46

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $1.72Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $75.1M

Enterprise Value $62.3M

Shares Outstanding 46M diluted

Next Earnings Date31 Oct 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Gain Therapeutics is a highly speculative, clinical-stage biotechnology company with a potentially paradigm-shifting lead asset, GT-02287, for the treatment of Parkinson's disease. By targeting the underlying causative biology of GCase enzyme misfolding, GT-02287 has demonstrated remarkable early disease-modifying signals, including an 81% average reduction in toxic CSF GluSph levels and stable MDS-UPDRS motor scores over 150 days of dosing. While the company faces severe going concern risks with a cash runway extending only into Q1 2027, the clinical validation of its Magellan platform and the massive unmet need in Parkinson's disease present an asymmetric risk-reward profile for risk-tolerant investors.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets5 analysts · as of 18 Aug 2026

Low · most bearish analyst$5.00

Mean target$7.20

High · most bullish analyst$8.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$1.0020%

The FDA requests additional preclinical or clinical safety data, delaying the initiation of the Phase 2 trial. Long-term data from the Phase 1b extension reveals safety concerns or a loss of biomarker efficacy. Unable to secure a strategic partner, the company is forced to raise capital under highly unfavorable terms, causing severe shareholder dilution, or faces a critical liquidity crisis as cash reserves deplete toward Q1 2027.

Base CaseCentral scenario

$7.2055%

Matches the consensus mean

The company receives FDA IND clearance and initiates its Phase 2 trial of GT-02287 in Q3 2026. Final Phase 1b extension data in Q4 2026 confirms the safety, tolerability, and durable biomarker efficacy of the drug. To fund the expensive Phase 2 program, Gain executes a dilutive equity financing of approximately $60 million, which temporarily depresses the stock price but secures the cash runway through 2028, allowing the stock to re-rate toward consensus analyst targets.

Bull CaseUpside scenario

$10.0025%

GT-02287 successfully transitions into Phase 2 clinical trials in Q3 2026 with rapid FDA clearance, demonstrating robust, statistically significant disease-modifying efficacy in a larger patient cohort. The company secures a lucrative global co-development partnership with a major pharmaceutical firm, completely resolving its going concern risk and eliminating near-term dilution. The Magellan platform is validated further by advancing preclinical assets like GT-04686 into IND-enabling studies, driving substantial valuation upside.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

First-in-class disease-modifying potential of lead asset GT-02287, targeting GCase misfolding to halt Parkinson's progression rather than just managing symptoms.
Compelling clinical biomarker validation, showing an 81% average reduction in toxic CSF GluSph levels and stable MDS-UPDRS motor scores over 150 days.
Proprietary Magellan drug discovery platform, which integrates AI and supercomputing to rapidly identify novel allosteric binding sites, creating a robust pipeline of preclinical assets.
Strong backing and validation from prestigious organizations, including funding from The Michael J. Fox Foundation and The Silverstein Foundation.

Key Investment Risks

Severe going concern risk, with current cash reserves of $16.5 million as of March 31, 2026, providing a runway only into Q1 2027.
High risk of near-term equity dilution, with analysts projecting a potential $60 million financing requirement to fund upcoming Phase 2 trials.
Clinical development and regulatory hurdles inherent to neurodegenerative drug candidates, which historically suffer from high failure rates in mid-to-late-stage trials.

Thesis Invalidation Triggers

Failure to obtain FDA IND clearance for the Phase 2 trial of GT-02287 by the end of 2026.
Emergence of serious adverse safety signals or a lack of durable efficacy in the final Phase 1b extension data readout.
Inability to secure additional financing or a strategic partnership before the end of 2026, leading to a severe liquidity crisis.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.